TW202312999A - 治療代謝病症之方法 - Google Patents

治療代謝病症之方法 Download PDF

Info

Publication number
TW202312999A
TW202312999A TW111135909A TW111135909A TW202312999A TW 202312999 A TW202312999 A TW 202312999A TW 111135909 A TW111135909 A TW 111135909A TW 111135909 A TW111135909 A TW 111135909A TW 202312999 A TW202312999 A TW 202312999A
Authority
TW
Taiwan
Prior art keywords
compound
individual
subject
glucose
insulin
Prior art date
Application number
TW111135909A
Other languages
English (en)
Chinese (zh)
Inventor
琳達 簡 布里斯托
尼娜 德狄奇
柯爾喬克 伊娃 哈喬斯
賽斯 卡博特 霍普金斯
菲利普 格林 瓊斯
肯尼斯 Ｓ 克伯蘭
斯內紮納 米拉諾維克
科琳 瑪麗 錫南
熊匡南
Original Assignee
美商蘇諾維恩藥業公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商蘇諾維恩藥業公司 filed Critical 美商蘇諾維恩藥業公司
Publication of TW202312999A publication Critical patent/TW202312999A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111135909A 2021-09-23 2022-09-22 治療代謝病症之方法 TW202312999A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163261515P 2021-09-23 2021-09-23
US63/261,515 2021-09-23
US202263362003P 2022-03-28 2022-03-28
US63/362,003 2022-03-28

Publications (1)

Publication Number Publication Date
TW202312999A true TW202312999A (zh) 2023-04-01

Family

ID=83902766

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111135909A TW202312999A (zh) 2021-09-23 2022-09-22 治療代謝病症之方法

Country Status (9)

Country Link
US (1) US20230241024A1 (https=)
EP (1) EP4404925A1 (https=)
JP (1) JP2024534580A (https=)
KR (1) KR20240110935A (https=)
AU (1) AU2022348905A1 (https=)
CA (1) CA3233074A1 (https=)
MX (1) MX2024003459A (https=)
TW (1) TW202312999A (https=)
WO (1) WO2023049721A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009049095A1 (de) 2009-10-01 2011-04-07 Alfred Kärcher Gmbh & Co. Kg Pumpe für ein Hochdruckreinigungsgerät
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
KR20250088777A (ko) * 2022-10-28 2025-06-17 스미토모 파마 아메리카, 인크. 불안 및 연관된 상태를 치료하기 위한 울로타론트
WO2025014889A2 (en) * 2023-07-07 2025-01-16 Procompounding, Llc Semaglutide formulations
US20250262185A1 (en) * 2024-02-16 2025-08-21 Sumitomo Pharma America, Inc. Methods of administering neuropsychiatric medications based on renal impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
JP2021513972A (ja) 2018-02-16 2021-06-03 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 社会的機能障害の治療方法
US20200179336A1 (en) 2018-12-06 2020-06-11 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders

Also Published As

Publication number Publication date
MX2024003459A (es) 2024-04-23
EP4404925A1 (en) 2024-07-31
WO2023049721A1 (en) 2023-03-30
CA3233074A1 (en) 2023-03-30
AU2022348905A1 (en) 2024-04-11
KR20240110935A (ko) 2024-07-16
JP2024534580A (ja) 2024-09-20
US20230241024A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
TW202312999A (zh) 治療代謝病症之方法
JP4787148B2 (ja) 新規アリールピペラジニル化合物
US6946464B2 (en) Methods of treating and preventing a convulsive state
JP2015157828A (ja) 睡眠障害および他の障害のための方法および組成物
US20210315859A1 (en) Methods of treating neurological and psychiatric disorders
JP6977024B2 (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法
US20120028991A1 (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
EP3661500B1 (en) Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
MX2014006689A (es) Derivados de 6-difluorometil-5,6-dihidro-2h-[1,4]oxazin-3-amina.
EP3903775A1 (en) R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
US10647679B2 (en) N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto
KR101396614B1 (ko) 7-［2-［4-(6-플루오로-3-메틸-1,2-벤즈이속사졸-5-일)-1-피페라지닐］에틸］-2-(1-프로피닐)-7Ｈ-피라졸로-［4,3-ｅ］-［1,2,4］-트리아졸로-［1,5-ｃ］-피리미딘-5-아민
WO2018023070A1 (en) Compounds and compositions and uses thereof
JP2010120916A (ja) 体内生理活性モノアミンの減少に関連して発症する精神・神経疾患の改善または治療剤
JP2025501411A (ja) 重水素化有機化合物およびその使用
US20250019357A1 (en) Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
KR20110013385A (ko) 주의력 결핍 장애 및 성기능 장애의 치료를 위한 3-히드록시 게피론
CN118488835A (zh) 治疗代谢障碍的方法
RU2456287C1 (ru) Стимуляторы секреции инкретиновых гормонов, способы их получения и применения
AU2015208233A1 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2022217247A1 (en) Isochroman derivatives and compositions and uses thereof
US20240182436A1 (en) Substituted sulfonamide-chroman compounds, and pharmaceutical compositions, and methods of use thereof
JP4555685B2 (ja) 肥満およびｃｎｓ障害の処置のための選択的ｄ１／ｄ５レセプターアンタゴニスト
TW200524885A (en) Morpholine derivatives as norepinephrine reuptake inhibitors
US20230279006A1 (en) Novel compounds and methods for increasing klotho gene expression